Rhenman & Partners Asset Management’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Rhenman & Partners Asset Management’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-38,000	Closed	-$4.37M	–	95
2014 Q4	$4.37M	Sell	38,000 -16,000	-30%	-$1.94M	1.27%	29
2014 Q3	$8.44M	Buy	54,000 +10,507	+24%	+$1.52M	2.47%	6
2014 Q2	$5.37M	Sell	43,493 -10,295	-19%	-$1.14M	1.59%	14
2014 Q1	$5.57M	Sell	53,788 -1,212	-2%	-$124K	1.67%	14
2013 Q4	$4.95M	Buy	+55,000	New	+$4.39M	1.94%	13

Other funds holding SLXP

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Rhenman & Partners Asset Management's SLXP Position: Q1 2015 in Review

Rhenman & Partners Asset Management sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2015, closing a stake of 38,000 shares — an estimated $4.37M sold.

Rhenman & Partners Asset Management first reported a position in SLXP in Q4 2013 and held it in 5 quarters. The position peaked at $8.44M in Q3 2014. 298 funds tracked by Wall St. Rank hold SLXP as of Q1 2015.

Rhenman & Partners Asset Management reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2015 after selling out during the quarter.
Rhenman & Partners Asset Management sold 38,000 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2015, an estimated $4.37M.
Rhenman & Partners Asset Management first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q4 2013 and held it in 5 quarters.
Rhenman & Partners Asset Management's SALIX PHARMACEUTICALS LTD DEL position peaked at $8.44M in Q3 2014.
298 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2015.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2015, filed 13 May 2015.